SG11201906289YA - Therapeutic agent for non-motor symptoms associated with parkinson's disease - Google Patents

Therapeutic agent for non-motor symptoms associated with parkinson's disease

Info

Publication number
SG11201906289YA
SG11201906289YA SG11201906289YA SG11201906289YA SG11201906289YA SG 11201906289Y A SG11201906289Y A SG 11201906289YA SG 11201906289Y A SG11201906289Y A SG 11201906289YA SG 11201906289Y A SG11201906289Y A SG 11201906289YA SG 11201906289Y A SG11201906289Y A SG 11201906289YA
Authority
SG
Singapore
Prior art keywords
parkinson
disease
symptoms
therapeutic agent
recurrence
Prior art date
Application number
SG11201906289YA
Inventor
Taro Kato
Satoko Shimizu
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of SG11201906289YA publication Critical patent/SG11201906289YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for 5 serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor .symptoms of Parkinson's disease; and a method for treating the aforesaid, symptoms or preventing the recurrence_ of the ,Same. A compound represented by 10 formula, (1) Awherein each symbol. is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of 15 Parkinson's disease and/or an effect of preventing the recurrence of the same. A R 7 R (1)
SG11201906289YA 2017-01-13 2018-01-12 Therapeutic agent for non-motor symptoms associated with parkinson's disease SG11201906289YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017004498 2017-01-13
PCT/JP2018/000568 WO2018131672A1 (en) 2017-01-13 2018-01-12 Therapeutic agent for non-motor symptoms associated with parkinson's disease

Publications (1)

Publication Number Publication Date
SG11201906289YA true SG11201906289YA (en) 2019-08-27

Family

ID=62840494

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201906289YA SG11201906289YA (en) 2017-01-13 2018-01-12 Therapeutic agent for non-motor symptoms associated with parkinson's disease
SG10201912846PA SG10201912846PA (en) 2017-01-13 2018-01-12 Therapeutic agent for non-motor symptoms associated with parkinson's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912846PA SG10201912846PA (en) 2017-01-13 2018-01-12 Therapeutic agent for non-motor symptoms associated with parkinson's disease

Country Status (11)

Country Link
US (2) US11576897B2 (en)
EP (1) EP3569233A4 (en)
JP (1) JP7219091B2 (en)
KR (1) KR20190105015A (en)
CN (1) CN110430875A (en)
AU (1) AU2018208321A1 (en)
CA (1) CA3049319A1 (en)
PH (1) PH12019501615A1 (en)
SG (2) SG11201906289YA (en)
TW (1) TWI761425B (en)
WO (1) WO2018131672A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219131B (en) 1991-10-18 2001-02-28 Monsanto Co. Method and fungicidal composition for the control of take-all disease of plants and the active ingredients
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US20060003996A1 (en) 2002-06-17 2006-01-05 Stephen Roth Intralesional treatment of psoriasis
EP1549639B1 (en) * 2002-10-07 2006-05-24 Glaxo Group Limited Sulphonamide derivatives as antipsychotic agents
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
TWI415845B (en) * 2006-10-03 2013-11-21 Arena Pharm Inc Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US8569353B2 (en) 2010-07-15 2013-10-29 Dainippon Sumitomo Pharma Co., Ltd. Pyrazole compound
JP2015129094A (en) * 2012-04-16 2015-07-16 大日本住友製薬株式会社 Arylaminopyrazole derivative

Also Published As

Publication number Publication date
JP7219091B2 (en) 2023-02-07
SG10201912846PA (en) 2020-02-27
EP3569233A1 (en) 2019-11-20
PH12019501615A1 (en) 2019-11-04
WO2018131672A1 (en) 2018-07-19
US11576897B2 (en) 2023-02-14
US20230149357A1 (en) 2023-05-18
JPWO2018131672A1 (en) 2019-11-07
CA3049319A1 (en) 2018-07-19
TW201831452A (en) 2018-09-01
US20210299099A1 (en) 2021-09-30
KR20190105015A (en) 2019-09-11
CN110430875A (en) 2019-11-08
TWI761425B (en) 2022-04-21
AU2018208321A1 (en) 2019-07-18
EP3569233A4 (en) 2020-09-30

Similar Documents

Publication Publication Date Title
MX2022010520A (en) Peptide macrocycles against acinetobacter baumannii.
MX2019003143A (en) Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof.
MX2023001876A (en) Rapamycin derivatives.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX368781B (en) Compound inhibiting kinase activities of btk and/or jak3.
NZ749911A (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
NZ726366A (en) Syk inhibitors
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MX2016015248A (en) Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy.
MX2022001697A (en) Pyrrolopyridine-aniline compounds for treatment of dermal disorders.
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
ZA202204666B (en) 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors
MX2017000208A (en) Quinolizinone derivatives as pi3k inhibitors.
JOP20180029A1 (en) Heterocyclic compound
MX2019006612A (en) IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS.
MX2021010122A (en) Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders.
MX2018009458A (en) Heterocyclic sulfonamide derivative and medicine containing same.
MX2022006229A (en) Compositions and methods for treatment of insulin resistance.
MX2020002630A (en) IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS.
MX2019007213A (en) Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicine.
PH12018502280A1 (en) Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
PH12016501645A1 (en) Aminopyrazolone derivative
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms